NICE sorts out antidiabetics in draft guideline
This article was originally published in Scrip
Executive Summary
A clinical guideline for treating type 2 diabetes in the national health service in England and Wales is being updated to include newer agents for blood glucose control. The National Institute for health and Clinical Excellence(NICE) has published a draft of the guideline for consultation, in which it considers the best use of depeptidyl peptidase-4 inhibitors, thiazolidinediones, the glucagon-like peptide-1 mimetic exenatide (Lilly's Byetta) and long-acting insulin analogues.